Donoghue Forlines LLC Regeneron Pharmaceuticals, Inc. Transaction History

Donoghue Forlines LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	SELL	$680.49 - $826.97 $30,622 - $37,213	-45 Reduced 8.98%	456 $374,000
Q4 2022 Feb 08, 2023	SELL	$705.89 - $766.39 $146,825 - $159,409	-208 Reduced 29.34%	501 $361,000
Q3 2022 Nov 07, 2022	SELL	$573.97 - $724.32 $927,535 - $1.17 Million	-1,616 Reduced 69.51%	709 $488,000
Q2 2022 Aug 08, 2022	BUY	$548.35 - $738.84 $598,249 - $806,074	1,091 Added 88.41%	2,325 $1.37 Million
Q1 2022 May 16, 2022	BUY	$595.12 - $698.43 $734,378 - $861,862	1,234 New	1,234 $862,000
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $1.26 Million - $1.52 Million	-2,308 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$493.32 - $643.92 $1.14 Million - $1.49 Million	2,308 New	2,308 $1.44 Million
Q2 2019 Jul 23, 2019	SELL	$299.6 - $414.82 $1.98 Million - $2.74 Million	-6,604 Closed	0 $0
Q1 2019 Apr 12, 2019	BUY	$372.08 - $439.57 $2.46 Million - $2.9 Million	6,604 New	6,604 $2.71 Million
Q4 2018 Jan 24, 2019	SELL	$335.82 - $403.04 $2.23 Million - $2.67 Million	-6,631 Closed	0 $0
Q3 2018 Oct 26, 2018	BUY	$351.14 - $408.51 $2.33 Million - $2.71 Million	6,631 New	6,631 $2.68 Million

1,487

85.7M

1.53M

1.43M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.5B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Donoghue Forlines LLC, based on Form 13F filings with the SEC.

Stay updated on Donoghue Forlines LLC with notifications on news.